#United States #Parkinson's Disease #Princeton #iQure Pharma #EAAT2

iQure Pharma's Significant Grant for Parkinson's Research

On June 18, 2026, iQure Pharma, a clinical-stage biotech company based in Princeton, New Jersey, announced a crucial development in the field of Parkinson's disease research. The company has received a prestigious research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) aimed at advancing their pioneering EAAT2 modulation program using their lead candidate, iQ-007.

The MJFF grant is part of its Parkinson's Disease Therapeutics Pipeline Program, an initiative designed to fund promising therapeutic approaches in the realm of Parkinson's disease. With Parkinson's affecting millions globally, innovations in treatment options are desperately needed. The funding will enable iQure Pharma to further investigate the mechanisms by which iQ-007 can balance glutamate levels—critical in maintaining neuronal health.

The Mechanism Behind EAAT2

The excitatory neurotransmitter glutamate must be tightly regulated within the brain to prevent toxicity and neuronal damage. EAAT2 (Excitatory Amino Acid Transporter 2) plays an essential role as it is primarily responsible for clearing surplus glutamate from synapses. In patients with Parkinson's disease and other cognitive disorders, dysfunction in this mechanism can lead to neuronal degradation. iQure Pharma's approach aims to enhance EAAT2 activity to halt this cycle of toxicity.

Dr. Henk de Wilde has been appointed as Principal Investigator for the program, collaborating with Associate Professor Laura Civiero from the University of Padova, a recognized expert in astroglial functions and their roles in neurodegeneration. Professor Civiero's research will extend beyond the MJFF-supported work, providing further insights into the mechanisms of iQ-007 and how it can address the underlying biological challenges faced by Parkinson’s patients.

Investigating Clinical Biomarkers

One of the grant's crucial aims is to identify clinical biomarkers that could help determine which patients would benefit from this new treatment. iQure Pharma plans to conduct studies across multiple preclinical models of Parkinson's disease. By understanding how iQ-007 interacts with various disease pathways, the research hopes to lay a foundation for tailored treatments in the future.

“I am thrilled about the potential this research holds,” said Pawel Zolnierczyk, CEO of iQure Pharma. “The award enables us to dive deeper into the effects of iQ-007 and its role in regulating glutamate levels, ultimately aiming to offer new hope for patients struggling with Parkinson’s.”

Significance of the Research

The implications of this grant and subsequent research extend beyond Parkinson's disease. Disruption of glutamate uptake is also involved in other central nervous system (CNS) disorders, including epilepsy and migraine. By developing iQ-007, iQure Pharma is not only seeking to provide groundbreaking treatments for Parkinson's but also exploring its efficacy across various neurological disorders.

As the project progresses, iQure Pharma aims to accumulate translational data that will guide future therapeutic developments and possibly position EAAT2 modulation as a viable treatment pathway for a spectrum of CNS diseases.

In conclusion, the partnership between iQure Pharma and The Michael J. Fox Foundation symbolizes a hopeful step forward in the fight against Parkinson's disease. By targeting the key mechanisms of neuronal damage through glutamate regulation, the researchers are paving the way for new therapeutic avenues that could change the landscape of how Parkinson's disease is treated.

For further information on iQure Pharma and its innovative approach, please visit their website at www.iqurepharma.com.